ASHP therapeutic position statement on the use of β-blockers in survivors of acute myocardial infarction

American Journal of Health-System Pharmacy

Volumn 59, Issue 22, 2002, Pages 2226-2232

[No Author Info available]

Author keywords

American Society of Health System Pharmacists; Contraindications; Drug use; Myocardial infarction; Organizations; Prescribing; Protocols; Rational therapy; Sympatholytic agents

Indexed keywords

ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; METOPROLOL; PROPRANOLOL; RAMIPRIL; TIMOLOL;

ACUTE HEART INFARCTION; ARTICLE; BETA ADRENERGIC RECEPTOR BLOCKING; BRADYCARDIA; BRONCHOSPASM; CARDIOVASCULAR RISK; CLINICAL PRACTICE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DRUG CONTRAINDICATION; ELDERLY CARE; HEART LEFT VENTRICLE FAILURE; HUMAN; HYPOTENSION; MEDICAL SOCIETY; MORTALITY; PATIENT SELECTION; PHARMACIST; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; TREATMENT PLANNING;

EID: 0037111758     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/59.22.2226     Document Type: Article

References (41)

1. Yusuf S, Peto R, Lewis J et al. Betablockade during and after myocardial infarction: An overview of randomized trials. Prog Cardiovasc Dis. 1985; 27:335-71.
2. Beta-Blocker Pooling Project Research Group. The Beta-Blocker Pooling Project (BBPP): Subgroup findings from randomized trials in post-MI patients. Eur Heart J. 1988; 9:8-16.
3. Ryan TJ, Antman EM, Brooks NH et al. 1999 Update: ACC/AHA guidelines for the management of patients with acute myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). J Am Coll Cardiol. 1999; 34:890-911.
4. McCormick D, Gurwitz JH, Lessard D et al. Use of aspirin, beta-blockers, and lipidlowering medications before recurrent acute myocardial infarction: Missed opportunities for prevention? Arch Intern Med. 1999; 159:561-7.
5. 2002 Heart and Stroke Statistical Update. Dallas, TX: American Heart Association; 2001.
6. Moss AJ, Benhorn J. Prognosis and management after a first myocardial infarction. N Engl J Med. 1990; 322:743-53.
7. May GS, Eberlein KA, Furberg CD et al. Secondary prevention after myocardial infarction: A review of long-term trials. Prog Cardiovasc Dis. 1982; 24:331-52.
8. Norwegian Multicenter Study Group. Timolol-induced reduction in mortality and re-infarction in patients surviving acute myocardial infarction. N Engl J Med. 1981; 304:801-7.
9. Pedersen TR. Six year follow-up of the Norwegian Multicenter Study on timolol after acute myocardial infarction. N Engl J Med. 1985; 313:1055-8.
10. Beta-Blocker Heart Attack Trial Research group. A randomized trial of propranolol in patients with acute myocardial infarction; mortality results. JAMA. 1982; 247: 1707-14.
11. Phillips BG, Yim JM, Brown EJ et al. Pharmacologic profile of survivors of acute myocardial infarction at United States academic hospitals. Am Heart J. 1996; 131:872-8.
12. Viskin S, Kitzis I, Lev E et al. Treatment with beta-adrenergic blocking agents after myocardial infarction: From randomized trials to clinical practice. J Am Coll Cardiol. 1995; 25:1327-32.
13. Meehan TP, Hennen J, Radford MJ et al. Process and outcome of care for acute myocardial infarction among Medicare beneficiaries in Connecticut: A quality improvement demonstration project. Ann Intern Med. 1995; 122:928-36.
14. Brand DA, Newcomer LN, Freiburger A et al. Cardiologist's practices compared with practice guidelines: Use of betablockade after acute myocardial infarction. J Am Coll Cardiol. 1995; 26:1432-6.
15. Barron HV, Viskin S, Lundstrom RJ et al. Beta-blocker dosages and mortality after myocardial infarction. Data from a large health maintenance organization. Arch Intern Med. 1998; 158:449-53.
16. Gunderson T, Abrahmsen AM, Kjekshus J et al. Timolol-related reduction in mortality and reinfarction in patients ages 65-75 years surviving acute myocardial infarction. Circulation. 1982; 66:1179-84.
17. Hawkins CM, Richardson DW, Vokonas PS. Effect of propranolol in reducing mortality in older myocardial infarction patients. The Beta-Blocker Heart Attack Trial experience. Circulation. 1983; 67(6, pt. 2):194-7.
18. Soumerai SB, McLaughlin TJ, Spiegelman D et al. Adverse outcomes of underuse of beta-blockers in elderly survivors of acute myocardial infarction. JAMA. 1997; 277:115-21.
19. Krumholz HM, Radford MJ, Wang Y et al. National use and effectiveness of betablockers for the treatment of elderly patients after acute myocardial infarction: National Cooperative Cardiovascular Project. JAMA. 1998; 280:623-9.
20. Chowdhury TA, Ladker SS, Dyer PH. Comparison of secondary prevention measures after myocardial infarction in subjects with and without diabetes mellitus. J Intern Med. 1999; 245:565-70.
21. Chen J, Marciniak TA, Radford MJ et al. Beta-blocker therapy for secondary prevention of myocardial infarction in elderly diabetic patients. Results from the National Cooperative Cardiovascular Project. J Am Coll Cardiol. 1999; 34: 1388-94.
22. Lowel H, Koenig W, Engel S et al. The impact of diabetes mellitus on survival after myocardial infarction: Can it be modified by drug treatment? Results of a population-based myocardial infarction register follow-up. Diabetologia. 2000; 43:218-26.
23. UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ. 1998; 317: 713-20.
24. Malmberg K, Ryden L, Hamsten A et al. Mortality prediction in diabetic patients with myocardial infarction: experience from the DIGAMI study. Cardiovasc Res. 1997; 34:248-53.
25. Lichstein E, Hager WD, Gregory JJ et al. Relation between beta-adrenergic blocker use, various correlates of left ventricular function and the chance of developing congestive heart failure. The Multicenter Diltiazem Post-Infarction Research Group. J Am Coll Cardiol. 1990; 16:1327-32.
26. Spargias KS, Hall AS, Greenwood DC et al. Beta-blocker treatment and other prognostic variables in patients with clinical evidence of heart failure after acute myocardial infarction: Evidence from the AIRE study. Heart. 1999; 81:25-32.
27. Furberg CD, Hawkins CM, Lichstein E et al., for the Beta-Blocker Heart Attack Trial Study Group. Effect of propranolol in postinfarction patients with mechanical or electrical complications. Circulation. 1984; 69:761-5.
28. Packer M, Bristow MR, Cohn JN et al., for the US Carvedilol Heart Failure Group. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med. 1996; 334:1349-55.
29. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999; 353: 2001-7.
30. CAPRICORN Investigators. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: The CAPRICORN randomized trial. Lancet. 2001; 357:1385-90.
31. Phillips KA, Shlipak MG, Coxson P et al. Health and economic benefits of increased beta-blocker use following myocardial infarction. JAMA. 2000; 284: 2748-54.
32. Holmboe ES, Meehan TP, Radford MJ et al. Use of critical pathways to improve the care of patients with acute myocardial infarction. Am J Med. 1999; 107:324-31.
33. Sarasin FP, Maschiangelo ML, Schaller MD et al. Successful implementation of guidelines for encouraging the use of beta-blockers in patients after acute myocardial infarction. Am J Med. 1999; 106:499-505.
34. Marciniak TA, Ellerbeck EF, Radford MJ et al. Improving the quality of care for Medicare patients with acute myocardial infarction: Results from the Cooperative Cardiovascular Project. JAMA. 1998; 279:1351-7.
35. Jencks SF, Cuerdon T, Burwen DR et al. Quality of medical care delivered to Medicare beneficiaries: A profile at state and national levels. JAMA. 2000; 284: 1670-6.
36. National Committee for Quality Assurance. The State of Managed Care Quality 2000. Washington, DC: National Committee for Quality Assurance; 2000.
37. Joint Commission on Accreditation for Healthcare Organizations. Plan for Introducing Joint Commission Hospital Core Measures Requirements. www. jcaho.org/oryx_frm.html (accessed 2001 Jan 22).
38. Cano SB, Lemoine K. Promoting optimal use of beta-blockers after myocardial infarction. Am J Health-Syst Pharm. 1999; 56:858-9.
39. Hilleman DE. Acute myocardial infarction. Paper presented at ASHP Midyear Clinical Meeting. Las Vegas, NV; 2000 Dec.
40. Mehta RH, Eagle KA. Secondary prevention in acute myocardial infarction. BMJ. 1998; 316:838-42.
41. Rochon PA, Tu JV, Anderson GM et al. Rate of heart failure and 1-year survival for older people receiving low-dose betablocker therapy after myocardial infarction. Lancet. 2000; 356:639-44.